hATTR Polyneuropathy in Russia

Plain-language summary

This observational study retrospectively examined the characteristics of patients in Russia with hereditary transthyretin amyloidosis polyneuropathy (hATTR-PN) or CIAP. It enrolled patients aged 18 and over who were diagnosed between January 1, 2017 and March 1, 2024. It was a study with no assigned phase and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Completed

Sponsor

AstraZeneca

Start date

12/29/2023

Estimated completion

5/30/2024

Countries

Russia

Related genes

Locations

• Kazan', Russia
• Moscow, Russia
• Saint Petersburg, Russia

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Patients with hATTR-PN or CIAP ;
* The diagnosis of hATTR-PN or CIAP was established between the 1st January 2017 and the 1st March 2024;
* Presence of at least 1 month between the date of hATTR-PN or CIAP diagnosis and the date of inclusion;
* Age ≥ 18 years at the time of hATTR-PN or CIAP diagnosis.

Exclusion Criteria:

* The participation in any clinical trial with investigational product from the moment of diagnosis of ATTR PN or CIAP until the end of retrospective follow-up period.